StockData
Alnylam Pharmaceuticals, Inc. logo

Alnylam Pharmaceuticals, Inc. (ALNY) stock

ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3047% below fair value
$149.40−7.10 (-4.54%)

Close on Nov 18, 2026Market cap $20.01BP/E 7.8Yield –

Alnylam Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Alnylam Pharmaceuticals's operating cash flow for the twelve months ending Sep 30, 2026 was $955.94M, up 351.6% year over year. For fiscal 2025 it was $524.08M. The highest annual figure on record is $524.08M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$524.08M–
FY2024Dec 31, 2024-$8.31M-108.0%
FY2023Dec 31, 2023$104.16M–
FY2022Dec 31, 2022-$541.27M–
FY2021Dec 31, 2021-$641.69M–
FY2020Dec 31, 2020-$614.96M–
FY2019Dec 31, 2019-$278.43M–
FY2018Dec 31, 2018-$562.62M–
FY2017Dec 31, 2017-$382.79M–
FY2016Dec 31, 2016-$307.70M–
FY2015Dec 31, 2015-$189.14M–
FY2014Dec 31, 2014-$165.64M–
FY2013Dec 31, 2013-$68.66M–
FY2012Dec 31, 2012-$115.61M–
FY2011Dec 31, 2011-$87.07M–
FY2010Dec 31, 2010-$84.34M–
FY2009Dec 31, 2009-$72.15M-210.2%
FY2008Dec 31, 2008$65.49M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$340.99M+14.9%
Q2 FY2026Jun 30, 2026$326.72M+151.7%
Q1 FY2026Mar 31, 2026$70.50M–
Q4 FY2025Dec 31, 2025$217.73M–
Q3 FY2025Sep 30, 2025$296.86M+579.2%
Q2 FY2025Jun 30, 2025$129.81M+4.5%
Q1 FY2025Mar 31, 2025-$120.31M–
Q4 FY2024Dec 31, 2024-$94.66M–
Q3 FY2024Sep 30, 2024$43.71M-87.8%
Q2 FY2024Jun 30, 2024$124.16M–
Q1 FY2024Mar 31, 2024-$81.52M–
Q4 FY2023Dec 31, 2023-$29.80M–
Q3 FY2023Sep 30, 2023$359.41M–
Q2 FY2023Jun 30, 2023-$58.99M–
Q1 FY2023Mar 31, 2023-$166.48M–
Q4 FY2022Dec 31, 2022-$131.98M–
Q3 FY2022Sep 30, 2022-$115.28M–
Q2 FY2022Jun 30, 2022-$122.82M–
Q1 FY2022Mar 31, 2022-$171.19M–
Q4 FY2021Dec 31, 2021-$150.14M–
Q3 FY2021Sep 30, 2021-$134.04M–
Q2 FY2021Jun 30, 2021-$121.86M–
Q1 FY2021Mar 31, 2021-$235.66M–
Q4 FY2020Dec 31, 2020-$123.14M–
Q3 FY2020Sep 30, 2020-$110.33M–
Q2 FY2020Jun 30, 2020-$135.33M-146.9%
Q1 FY2020Mar 31, 2020-$246.16M–
Q4 FY2019Dec 31, 2019-$195.98M–
Q3 FY2019Sep 30, 2019-$182.63M–
Q2 FY2019Jun 30, 2019$288.70M–
Q1 FY2019Mar 31, 2019-$188.51M–
Q4 FY2018Dec 31, 2018-$150.46M–
Q3 FY2018Sep 30, 2018-$153.81M–
Q2 FY2018Jun 30, 2018-$102.69M–
Q1 FY2018Mar 31, 2018-$155.66M–
Q4 FY2017Dec 31, 2017-$103.04M–
Q3 FY2017Sep 30, 2017-$98.36M–
Q2 FY2017Jun 30, 2017-$81.05M–
Q1 FY2017Mar 31, 2017-$100.33M–
Q4 FY2016Dec 31, 2016-$78.34M–

More Alnylam Pharmaceuticals figures

See a number that looks wrong?